Front Row Advisors’s Medpace MEDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.78M Sell
7,863
-70
-0.9% -$35.8K 1.28% 17
2025
Q4
$4.46M Sell
7,933
-5
-0.1% -$2.84K 1.49% 13
2025
Q3
$4.08M Sell
7,938
-1,503
-16% -$656K 1.37% 14
2025
Q2
$2.96M Buy
9,441
+35
+0.4% +$10.5K 1.03% 22
2025
Q1
$2.87M Sell
9,406
-3
-0% -$1.01K 1.1% 23
2024
Q4
$3.13M Buy
9,409
+9
+0.1% +$3.05K 1.08% 24
2024
Q3
$3.14M Buy
9,400
+114
+1% +$43.3K 1.12% 23
2024
Q2
$3.82M Sell
9,286
-1,650
-15% -$653K 1.33% 15
2024
Q1
$4.42M Sell
10,936
-5
-0% -$1.76K 1.64% 11
2023
Q4
$3.35M Buy
10,941
+20
+0.2% +$5.4K 1.54% 14
2023
Q3
$2.64M Buy
10,921
+55
+0.5% +$14.1K 1.22% 19
2023
Q2
$2.61M Sell
10,866
-304
-3% -$63.1K 1.16% 22
2023
Q1
$2.1M Buy
11,170
+15
+0.1% +$3.1K 1.01% 25
2022
Q4
$2.37M Sell
11,155
-684
-6% -$137K 1.22% 22
2022
Q3
$1.86M Buy
11,839
+60
+0.5% +$9.57K 0.96% 29
2022
Q2
$1.76M Sell
11,779
-15
-0.1% -$2.17K 0.87% 36
2022
Q1
$1.93M Buy
11,794
+985
+9% +$162K 0.78% 40
2021
Q4
$2.35M Buy
10,809
+409
+4% +$85.6K 0.88% 34
2021
Q3
$1.97M Buy
10,400
+150
+1% +$27.4K 0.83% 39
2021
Q2
$1.81M Buy
10,250
+710
+7% +$123K 0.74% 46
2021
Q1
$1.56M Buy
9,540
+555
+6% +$84.9K 0.76% 45
2020
Q4
$1.25M Sell
8,985
-60
-0.7% -$7.56K 0.64% 52
2020
Q3
$1.12M Buy
9,045
+65
+0.7% +$7.52K 0.59% 52
2020
Q2
$835K Sell
8,980
-55
-0.6% -$4.68K 0.52% 55
2020
Q1
$722K Buy
+9,035
New +$784K 0.49% 58

Other funds holding MEDP

Front Row Advisors's MEDP Position: Q1 2026 in Review

Front Row Advisors reduced its Medpace (MEDP) stake by 0.88% in Q1 2026, selling an estimated $35.8K and leaving 7,863 shares worth $3.78M. The position accounts for 1.28% of the portfolio, ranked #17.

Front Row Advisors first reported a position in MEDP in Q1 2020 and has held it in 25 quarters since. The position peaked at $4.46M in Q4 2025. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

  • Front Row Advisors held 7,863 shares of Medpace worth $3.78M as of Q1 2026.
  • Front Row Advisors sold 70 Medpace shares in Q1 2026, an estimated $35.8K.
  • Medpace made up 1.28% of Front Row Advisors's portfolio in Q1 2026, its #17 holding.
  • Front Row Advisors first reported a position in Medpace in Q1 2020 and has held it in 25 quarters since.
  • Front Row Advisors's Medpace position peaked at $4.46M in Q4 2025.
  • 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.